Section 9, Pharmacologic Approaches to Glycemic Treatment, of the Standards of Medical Care in Diabetes—2020 has been annotated based on a U.S. Food and Drug Administration Drug Safety Communication.
The online version of the article (https://doi.org/10.2337/dc20-S009) reflects the changes described below.
The following sentence has been added to the “Additional considerations” column for SGLT2 inhibitors in Table 9.1 (p. S101):
“FDA safety labeling recommends temporary discontinuation of SGLT2 inhibitors before any scheduled surgery to avoid potential risk for diabetic ketoacidosis.”
References
U.S. Food and Drug Administration
. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 19 March 2020 update [FDA Drug Safety Communication]. Available from
https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious© 2020 by the American Diabetes Association
2020
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.
